


ONIVYDE: SPECIFICALLY DESIGNED TO FIGHT PANCREATIC CANCER

ONIVYDE[®] pegylated liposomal irinotecan is approved for metastatic adenocarcinoma of the pancreas in combination with 5-fluorouracil (5-FU) and leucovorin (LV), in adult patients who have progressed following gemcitabine-based therapy¹



1. ONIVYDE EU Summary of Product Characteristics. Available at: <http://www.medicines.org.uk/emc/product/9200/smpc>. Last accessed July 2020



onivyde[®]
pegylated liposomal irinotecan